Chinese medicine companies "hurry up for exams": group competitions, quota purchases!

On Christmas Eve just past, many Chinese patent medicine companies and related alliances unexpectedly received special "gifts": December 24 was the deadline for the announcement of the results of the procurement of the 19 provincial Chinese patent medicine inter-provincial alliances led by Hubei.

At the end of the year, another surprise came from the Chinese medicine sector once again leading the tide

In 2022, the differentiation and evolution of the Chinese patent medicine industry will become more apparent, and a new road to rushing to the exam will begin quietly

Pattern: price difference "candidates", which is better for AB unit?

TOP10 products of proprietary Chinese medicines in public hospitals in key cities in the first quarter of 2021

The two alliances that are the first to try first adopt the form of A and B competition units for centralized procurement

The reason is that proprietary Chinese medicines are affected by many factors, but the industry's feedback is more concentrated on prices

Looking at the Guangdong Alliance, which has yet to open bids, the competition scene is roughly similar: the most typical one is Tasly’s exclusive product 27mg compound salvia miltiorrhiza dripping pills.

In addition, the quota for procurement has also intensified the formation of competition

  Furthermore, from the perspective of provinces, the two alliances mentioned above overlap in Shanxi, Henan, Hainan, and Ningxia.

Strategy: Who will go first in academic research and channel coverage?

  It can also be seen from the centralized procurement documents that there is a huge difference in the amount of reports obtained by different companies: for example, the amount reported by public medical institutions in the 6-province alliance in Guangdong, motherwort granules 3g/15g specifications, the minimum pre-purchasing amount in the first year of the purchase period is only 20 (pieces/ Tablets/bags/sticks), the corresponding companies are Chengdu No.

  How to stand out on the new track? Academic research is moving towards the front, and terminal coverage is spreading towards the grassroots

  This is the conclusion drawn from the analysis of the varieties included in the two major alliances: Taking Xianling Gubao 0.

  Shanghai Hutchison Pharmaceutical's 22.

  Sales of Musk Baoxin Pills in  China's public medical institutions in the first half of 2015-2020 (unit: ten thousand yuan)